Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Evaluation of current therapeutic strategies in Behçet’s disease

  • 399 Accesses

  • 20 Citations


Behçet’s disease (BD) is a chronic relapsing vasculitis with multifunctional pathogenesis. The mucocutaneous and ocular lesions are the commonest manifestations, but BD also affects the musculoskeletal, intestinal, cardiac, and central nervous system. BD therapy is based on the suppression of the inflammatory process, using immunomodulating and immunosuppressive agents. In selected cases, invasive procedures may be required.

This is a preview of subscription content, log in to check access.



Behcet disease




Tumor Necrosis Factor




Cyclosporin A




Interferon α


Antinuclear antibodies


Matrix metalloprotease


Central nervous system


Cerebrospinal fluid


  1. 1.

    Alpsoy E, Akman A (2009) Behçet’s disease: an algorithmic approach to its treatment. Arch Dermatol Res 301:693–702

  2. 2.

    Ahmad T, Wallace GR, James T et al (2003) Mapping the HLA association in Behçet’s disease: a role for tumor necrosis factor polymorphisms? Arth Rheum 48:807–813

  3. 3.

    Ceyran H, Akcali Y, Kahraman C (2003) Surgical treatment of vasculo-Behçet’s disease. A review of patients with concomitant multiple aneurysms and venous lesions. Vasa 32:149–153

  4. 4.

    Kapsimali V, Kanakis M, Vaiopoulos G, et al (2010) Etiopathogenesis of Behçet’s disease with emphasis on the role of immunological aberrations. Clin Rheumatol (in press)

  5. 5.

    Calamia KT, Kaklamanis PG (2008) Behçet’s disease: recent advances in early diagnosis and effective treatment. Curr Rheumatol Rep 10:349–355

  6. 6.

    Gul A (2007) Standard and novel therapeutic approaches to Behçet’s disease. Drugs 67:2013–2022

  7. 7.

    Sfikakis PP, Theodossiadis PG, Katsiari CG et al (2001) Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358:295–296

  8. 8.

    Lynde CB, Bruce AS, Rogers RS 3rd (2009) Successful treatment of complex aphthosis with colchicine and dapsone. Arch Dermatol 145:273–276

  9. 9.

    Debol SM, Herron MJ, Nelson RD (1997) Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 62:827–836

  10. 10.

    Kaklamanis P, Kaklamani V (2001) Treatment of Behçet’s disease—an update. Semin Arth Rheum 30:299–312

  11. 11.

    Hatemi G, Silman A, Bang D et al (2009) Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis 68:1528

  12. 12.

    Seyahi E, Fresko I, Yazici H et al (2006) The management of Behcet syndrome. Acta Rheum Port 31:125–131

  13. 13.

    Lin P, Liang G (2006) Behçet disease: recommendation for clinical management of mucocutaneous lesions. J Clin Rheumatol 12:282–286

  14. 14.

    Duygulu F, Evereklioglu MM et al (2005) Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Behçet’s disease: a pilot study. Clin Rheumatol 24:324–330

  15. 15.

    Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti-TNF therapy in the management of Behcet’s disease—review and basis for recommendations. Rheumatology (Oxford) 46:736–741

  16. 16.

    Dé Tran QH, Guay E, Chartier S, Tousignant J (2001) Tacrolimus in dermatology. J Cutan Med Surg 5:329–335

  17. 17.

    Bruynzeel I, Van Der Raaij LM, Willemze R, Stoof TJ (1997) Pentoxifylline inhibits human T-cell adhesion to dermal endothelial cells. Arch Dermatol Res 289:189–193

  18. 18.

    Funk JO, Ernst M, Schonharting MM, Zabel P (1995) Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporin A. Int J Immunopharmacol 17:1007–1016

  19. 19.

    Zouboulis CC, Orfanos CE (1998) Treatment of Adamantiades-Behçet disease with systemic interferon alfa. Arch Dermatol 134:1010–1016

  20. 20.

    Nakamura T, Yagi H, Kurachi K, Konno H (2006) Intestinal Behcet’s disease with pyoderma gangrenosum: a case report. World J Gastroenterol 12:979–981

  21. 21.

    Fresko I, Yazici H (2008) Treatment strategies for Behçet’s disease. Expert Opin Pharmacother 9:3211–3219

  22. 22.

    Choi IJ, Kim JS, Cha SD et al (2000) Long-term clinical course and prognostic factors in intestinal Behçet’s disease. Dis Colon Rectum 43:692–700

  23. 23.

    Lee KS, Kim SJ, Lee BC et al (1997) Surgical treatment of intestinal Behçet’s disease. Yonsei Med J 38:455–460

  24. 24.

    Kurata M, Nozue M, Seino K et al (2006) Indications for surgery in intestinal Behçet’s disease. Hepatogastroenterology 53:60–63

  25. 25.

    Sapadin AN, Fleischmajer R (2006) Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54:258–265

  26. 26.

    Deuter CM, Kotter I, Wallace GR et al (2008) Behçet’s disease: ocular effects and treatment. Prog Retin Eye Res 27:111–136

  27. 27.

    Kaçmaz RO, Kempen JH, Newcomb C et al (2008) Systemic immunosuppressive therapy for eye diseases cohort study group. Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 146:828–836

  28. 28.

    Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of Infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine and corticosteroids in Behcet disease: an open-label trial. Arthritis Rheum 52:2478–2484

  29. 29.

    Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 322:281–285

  30. 30.

    Akman-Demir G, Ayranci O, Kurtuncu M et al (2008) Cyclosporine for Behçet’s uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol 26(Suppl):S84–S90

  31. 31.

    Krause L, Altenburg A, Pleyer U et al (2008) Longterm visual prognosis of patients with ocular Adamantiades-Behçet’s disease treated with interferon-alpha-2a. J Rheumatol 35:896–903

  32. 32.

    Tugal-Tutkun I, Onal S, Altan-Yaycioglu R et al (2006) Neovascularization of the optic disc in Behçet’s disease. Jpn J Ophthalmol 50:256–265

  33. 33.

    Sfikakis PP (2002) Behçet’s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61(Suppl 2):ii51–ii53

  34. 34.

    Elezoglou A, Kafasi N, Kaklamanis PH et al (2007) Infliximab treatment-induced formation of autoantibodies is common in Behçet’s disease. Clin Exp Rheumatol 25(Suppl):S65–S69

  35. 35.

    Krause L, Altenburg A, Bechrakis NE et al (2007) Intraocular surgery under systemic interferon-alpha therapy in ocular Adamantiades-Behçet’s disease. Graefes Arch Clin Exp Ophthalmol 245:1617–1621

  36. 36.

    Elgin U, Berker N, Batman A, Soykan E (2007) Nd:YAG laser iridotomy in the management of secondary glaucoma associated with Behçet’s disease. Eur J Ophthalmol 17:191–195

  37. 37.

    Sullu Y, Alotaiby H, Beden U, Erkan D (2005) Pars plana vitrectomy for ocular complications of Behçet’s disease. Ophthalmic Surg Lasers Imaging 36:292–297

  38. 38.

    Soylu M, Demircan N, Pelit A (2001) Pars plana vitrectomy in ocular Behçet’s disease. Int Ophthalmol 24:219–223

  39. 39.

    Han JK, Kim HK, Kim YJ et al (2009) Behçet’s disease as a frequently unrecognized cause of aortic regurgitation: suggestive and misleading echocardiography findings. J Am Soc Echocardiogr 22:1269–1274

  40. 40.

    Marzban M, Mandegar MH, Karimi A et al (2008) Cardiac and great vessel involvement in “Behcet’s disease”. J Card Surg 23:765–768

  41. 41.

    Imazio M, Brucato A, Trinchero R et al (2009) Colchicine for pericarditis: hype or hope? Eur Heart J 30:532–539

  42. 42.

    Arishiro K, Nariyama J, Hoshiga M et al (2006) Vascular Behçet’s disease with coronary artery aneurysm. Intern Med 45:903–907

  43. 43.

    Ozen S, Bilginer Y, Besbas N et al (2010) Behçet disease: treatment of vascular involvement in children. Eur J Pediatr 169:427–430

  44. 44.

    Oh SH, Lee JH, Shin JU, Bang D (2008) Dermatological features in Behçet disease-associated vena cava obstruction. Br J Dermatol 159:555–560

  45. 45.

    Alpagut U, Ugurlucan M, Dayioglu E (2007) Major arterial involvement and review of Behçet’s disease. Ann Vasc Surg 21:232–239

  46. 46.

    Abdul-Hussien H, Hanemaaijer R, Verheijen JH et al (2009) Doxycycline therapy for abdominal aneurysm: improved proteolytic balance through reduced neutrophil content. J Vasc Surg 49:741–749

  47. 47.

    Siva A, Saip S (2009) The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis. J Neurol 256:513–529

  48. 48.

    Borhani Haghighi A (2009) Treatment of neuro-Behçet’s disease: an update. Expert Rev Neurother 9:565–574

  49. 49.

    Gono T, Murata M, Kawaguchi Y et al (2009) Successful treatment for sympathetic storms in a patient with neuro-Behçet’s disease. Clin Rheumatol 28:357–359

Download references



Author information

Correspondence to Iliana Alexoudi.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Alexoudi, I., Kapsimali, V., Vaiopoulos, A. et al. Evaluation of current therapeutic strategies in Behçet’s disease. Clin Rheumatol 30, 157–163 (2011).

Download citation


  • Behcet’s disease
  • Biologic agents
  • Management
  • Organs
  • Therapy
  • Treatment